A
Andrew Plummer
Researcher at University of Modena and Reggio Emilia
Publications - 9
Citations - 1411
Andrew Plummer is an academic researcher from University of Modena and Reggio Emilia. The author has contributed to research in topics: Elvitegravir/cobicistat/emtricitabine/tenofovir & Emtricitabine. The author has an hindex of 7, co-authored 9 publications receiving 1280 citations.
Papers
More filters
Journal ArticleDOI
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials
Paul E. Sax,David A. Wohl,Michael Yin,Frank A. Post,Edwin DeJesus,Michael S. Saag,Anton Pozniak,Melanie Thompson,Daniel Podzamczer,Jean-Michel Molina,Shinichi Oka,Ellen Koenig,Benoit Trottier,Jaime Andrade-Villanueva,Gordon Crofoot,Joseph M. Custodio,Andrew Plummer,Lijie Zhong,Huyen Cao,Hal Martin,Christian Callebaut,Andrew K. Cheng,Marshall W. Fordyce,Scott McCallister +23 more
TL;DR: Renal and bone effects were significantly reduced in patients given E/C/F/tenofovir alafenamide or E-C-F-tenofavir disoproxil fumarate and the main outcomes were the proportion of patients with plasma HIV-1 RNA less than 50 copies per mL at week 48 as defined by the US Food and Drug Adminstration snapshot algorithm and pre-specified renal and bone endpoints at 48 weeks.
Journal ArticleDOI
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study
Anthony Mills,Jose R. Arribas,Jaime Andrade-Villanueva,Giovanni DiPerri,Jan van Lunzen,Ellen Koenig,Richard Elion,Matthias Cavassini,Jose V aldez Madruga,Jason Brunetta,David Shamblaw,Edwin DeJesus,Chloe Orkin,David A. Wohl,Indira Brar,Jeffrey L. Stephens,Pierre Marie Girard,Gregory D Huhn,Andrew Plummer,Ya Pei Liu,Andrew K. Cheng,Scott McCallister +21 more
TL;DR: Switching to a tenofovir alafenamide-containing regimen from one containing ten ofovir disoproxil fumarate was non-inferior for maintenance of viral suppression and led to improved bone mineral density and renal function.
Journal ArticleDOI
Brief Report: Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: Week 144 Results.
Jose R. Arribas,Melanie Thompson,Paul E. Sax,Bernhard Haas,Cheryl McDonald,David A. Wohl,Edwin DeJesus,Amanda Clarke,Susan Guo,Hui Wang,Christian Callebaut,Andrew Plummer,Andrew K. Cheng,Das M,Scott McCallister +14 more
TL;DR: Longer-term data support E/C/F/TAF as a safe, well-tolerated, and durable regimen for initial HIV-1 treatment.
Journal ArticleDOI
A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 results.
Andrew R. Zolopa,Paul E. Sax,Edwin DeJesus,Anthony Mills,Calvin J. Cohen,David A. Wohl,Joel E. Gallant,Hui C. Liu,Andrew Plummer,Kirsten L. White,Andrew K. Cheng,Martin S. Rhee,Javier Szwarcberg +12 more
TL;DR: These results support the durable efficacy and long-term safety of EVG/COBI/FTC/TDF and efavirenz/emtricitabine/tenofovir disoproxil fumarate.
Journal ArticleDOI
Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial
Joel E. Gallant,Eric S. Daar,François Raffi,Cynthia Brinson,Peter Ruane,Edwin DeJesus,Margaret Johnson,Nathan Clumeck,Olayemi Osiyemi,Doug Ward,Javier O Morales-Ramirez,Mingjin Yan,Michael E. Abram,Andrew Plummer,Andrew K. Cheng,Martin S. Rhee +15 more
TL;DR: With its safety advantages, fixed-dose emtricitabine with tenofovir alafenamide has the potential to become an important NRTI backbone.